Literature DB >> 29079901

Diabetes and the Pancreatobiliary Diseases.

Muhammad Shafqet1, Kaveh Sharzehi2.   

Abstract

PURPOSE OF REVIEW: The emphasis of this review article is to bring to the forefront the spectrum of pancreatobiliary disorders and their association with diabetes. We hope to systematically discuss the link between diabetes and disorders of the pancreas including acute and chronic pancreatitis, as well as pancreatic cancer. We also hope to review and highlight the literature with respect to other cancers of the biliary tree including gallbladder and cholangiocarcinoma. Lastly, we discuss diabetes and biliary dyskinesia. RECENT
FINDINGS: Newer cohort studies suggest the presence of diabetes to increase the severity and worsen outcomes in acute pancreatitis. Post pancreatitis diabetes is a novel disease entity being increasingly recognized. The use of pancreatic enzyme replacement therapy (PERT) in chronic pancreatitis may attenuate the risk of endocrine dysfunction. Pancreatic cancer may either be the consequence of diabetes or a presenting manifestation. The use of anti-diabetic medications may confer protection against development of pancreatic cancer. Gallbladder adenocarcinoma and cholangiocarcinoma risks are elevated in those with underlying diabetes. Diabetes can directly impact or deteriorate outcome of acute and chronic pancreatitis and well as pancreatobiliary malignancies. It could also occur as a result of loss of endocrine function after pancreatitis. Like many areas of the digestive tract, biliary motility could be impacted by diabetes.

Entities:  

Keywords:  Acute pancreatitis; Biliary carcinoma; Biliary dyskinesia; Chronic pancreatitis; Diabetes mellitus; Pancreatic carcinoma

Year:  2017        PMID: 29079901     DOI: 10.1007/s11938-017-0163-x

Source DB:  PubMed          Journal:  Curr Treat Options Gastroenterol        ISSN: 1092-8472


  53 in total

1.  The Long-term Prospective Follow-up of Pancreatic Function After the First Episode of Acute Alcoholic Pancreatitis: Recurrence Predisposes One to Pancreatic Dysfunction and Pancreatogenic Diabetes.

Authors:  Jussi Nikkola; Johanna Laukkarinen; Jorma Lahtela; Hanna Seppänen; Satu Järvinen; Isto Nordback; Juhani Sand
Journal:  J Clin Gastroenterol       Date:  2017-02       Impact factor: 3.062

Review 2.  Organ failure and infection of pancreatic necrosis as determinants of mortality in patients with acute pancreatitis.

Authors:  Maxim S Petrov; Satyanarayan Shanbhag; Mandira Chakraborty; Anthony R J Phillips; John A Windsor
Journal:  Gastroenterology       Date:  2010-06-09       Impact factor: 22.682

3.  Impaired gallbladder motility in adults with newly detected type 2 diabetes and lack of reversibility after achieving euglycemia.

Authors:  Faheem Arshad; Bashir Ahmad Laway; Tanveer Ahmad Rather; Mohammad Shafi Kuchay; Shoukat Hussain Khan
Journal:  Can J Diabetes       Date:  2014-11-13       Impact factor: 4.190

4.  APACHE-II score for assessment and monitoring of acute pancreatitis.

Authors:  M Larvin; M J McMahon
Journal:  Lancet       Date:  1989-07-22       Impact factor: 79.321

5.  Plasma insulin, serum lipids and lipoproteins in gall stone disease in non-insulin dependent diabetic subjects: a case control study.

Authors:  M Laakso; M Suhonen; R Julkunen; K Pyörälä
Journal:  Gut       Date:  1990-03       Impact factor: 23.059

6.  Gallbladder motility in diabetes mellitus using real time ultrasonography.

Authors:  J S Hahm; J Y Park; K G Park; Y H Ahn; M H Lee; K N Park
Journal:  Am J Gastroenterol       Date:  1996-11       Impact factor: 10.864

7.  Effect of acute hyperglycaemia on gall bladder contraction induced by cholecystokinin in humans.

Authors:  S Y de Boer; A A Masclee; M C Jebbink; J Schipper; H H Lemkes; J B Jansen; C B Lamers
Journal:  Gut       Date:  1993-08       Impact factor: 23.059

8.  Real-time sonography for screening of gallbladder motility in diabetic patients: relation to autonomic and peripheral neuropathy.

Authors:  Ertugrul Kayacetin; Gurcan Kisakol; Ahmet Kaya; Zehra Akpinar
Journal:  Neuro Endocrinol Lett       Date:  2003 Feb-Apr       Impact factor: 0.765

Review 9.  Metformin is associated with reduced risk of pancreatic cancer in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.

Authors:  Zheng Wang; Song-Tao Lai; Li Xie; Jian-Dong Zhao; Ning-Yi Ma; Ji Zhu; Zhi-Gang Ren; Guo-Liang Jiang
Journal:  Diabetes Res Clin Pract       Date:  2014-04-18       Impact factor: 5.602

10.  Risk Factors for Diabetes Mellitus in Chronic Pancreatitis: A Cohort of 2,011 Patients.

Authors:  Jun Pan; Lei Xin; Dan Wang; Zhuan Liao; Jin-Huan Lin; Bai-Rong Li; Ting-Ting Du; Bo Ye; Wen-Bin Zou; Hui Chen; Jun-Tao Ji; Zhao-Hong Zheng; Liang-Hao Hu; Zhao-Shen Li
Journal:  Medicine (Baltimore)       Date:  2016-04       Impact factor: 1.889

View more
  4 in total

1.  Incidence and causes of mildly to moderately elevated aminotransferase in Japanese patients with type 2 diabetes.

Authors:  Chia-Hsien Chang; Motonobu Sakaguchi
Journal:  Diabetol Int       Date:  2019-08-14

2.  Underexpression of miR-126-3p in Patients with Cholangiocarcinoma.

Authors:  Lucas Poleto Spinola; Gabriel F Vieira; Rafael Fernandes Ferreira; Maria C J Calastri; Graciele D Tenani; Franciana L Aguiar; Ilka F Santana Ferreira Boin; Larissa B E Da Costa; Maria Fernanda Chaim Correia; Eliane M Zanovelo; Daniele C B De Souza; Rita C Martins Alves Da Silva; Renato Ferreira Da Silva; Ana Margarida Coelho Abrantes; Maria Filomena R R Botelho; Jose Guilherme L R Tralhão; Doroteia R S Souza
Journal:  Asian Pac J Cancer Prev       Date:  2021-02-01

3.  Erectile Dysfunction in Men With Gallbladder Stone Disease: A Nationwide Population-Based Study.

Authors:  Chien-Hua Chen; Cheng-Li Lin; Chia-Hung Kao
Journal:  Am J Mens Health       Date:  2019 Mar-Apr

4.  Exploring and validating the clinical risk factors for pancreatic cancer in chronic pancreatitis patients using electronic medical records datasets: three cohorts comprising 2,960 patients.

Authors:  Xin Zhao; Ren Lang; Zhigang Zhang; Weiling Zhao; Zhiwei Ji; Hua Tan; Xiaobo Zhou
Journal:  Transl Cancer Res       Date:  2020-02       Impact factor: 1.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.